Frederic W Grannis

Prof. Dr. Frederic W Grannis

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2010 in Cancer
Verified
Journal Article
Open access
PDF file
TWTina Wang
Tina Wang
RNRebecca A. Nelson
Rebecca A. Nelson
ABAlicia Bogardus
Alicia Bogardus
FGFrederic W Grannis
Frederic W Grannis
BACKGROUND: The core strategy of American College of Chest Physicians lung cancer guidelines is identification of the earliest symptoms of lung cancer and the immediate initiation of diagnosis and treatment. In the absence of screening, most symptomatic lung cancer is discovered at advanced stages, with the goal of long‐term survival entirely dependent on effective treatment of stage III and IV lung cancer.METHODS: In a retrospective review, all patients diagnosed with stage IIIA, IIIB, and IV nonsmall cell lung cancer (NSCLC) between the years 1986 and 2001 at City of Hope National Medical Center who survived 5 years or longer were analyzed to identify parameters that might predict long‐term survival.RESULTS: Of 846 patients presenting with stage III or IV disease, 56 (6.6%) survived 5 years or longer. Sixteen patients died of primary tumor progression beyond 5 years. Two 5‐year survivors died of second tobacco‐caused neoplasms, and 16 died from medical conditions potentially related to prior treatment. A substantial majority of survivors were from specific pathologic subsets including: 1) resectable N2 disease (n = 17, 30.4%), 2) multiple lung tumors (n = 7, 12.5%), 3) T3N0 (n = 5, 8.1%), and 4) single site distant metastasis (n = 8, 14.2%).CONCLUSIONS: Despite aggressive multimodality therapy, 5‐year survival in patients with advanced stage NSCLC was very poor and limited to small pathological subsets. Patients with advanced stage NSCLC who did not belong to 1 of these subsets had a small chance of long‐term survival. Cancer 2010. © 2010 American Cancer Society.

1 April 2011 in Surgical Clinics of North America
Verified
Journal Article
Closed access
BFBetty Ferrell
Betty Ferrell
MKMarianna Koczywas
Marianna Koczywas
FGFrederic W Grannis
Frederic W Grannis
AHAnnie Harrington
Annie Harrington

1 August 2002 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
JLJeffrey P. Lamont
Jeffrey P. Lamont
JKJames T. Kakuda
James T. Kakuda
DSDavid Smith
David Smith
LWLawrence D. Wagman
Lawrence D. Wagman
FGFrederic W Grannis
Frederic W Grannis
IT IS ESTIMATED that 169 400 people will be diagnosed as having lung cancer in the United States in 2002.1 The 5-year cure rate has risen from 6% to 14% during the past 50 years. Of patients who survive a first non–small cell lung cancer (NSCLC), many develop a second cancer, either a second primary lung cancer (SPLC) or locally recurrent lung cancer (LRLC). Survival after recurrent lung cancer has been dismal owing to the inability to diagnose these lesions at an early stage. Indeed, 38% of SPLCs are not resected because of locally advanced tumors at diagnosis.2 Survival after SPLC ranges from 4% to 32% in various series,3-5 and LRLCs have 2-year survival of approximately 23%. Because of these poor results, some experts6,7 believe that comprehensive postsurgical follow-up by thoracic surgeons is not indicated.

30 January 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
JMJames L. Mulshine
James L. Mulshine
BPBruce Pyenson
Bruce Pyenson
CHCheryl Healton
Cheryl Healton
CACarolyn Aldige
Carolyn Aldige
RARiccardo S. Avila
Riccardo S. Avila
MOMatthijs Oudkerk
Matthijs Oudkerk

18 August 2009 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ACA W Castleberry
A W Castleberry
DSDavid Smith
David Smith
CAC Anderson
C Anderson
ARA J Rotter
A J Rotter
FGFrederic W Grannis
Frederic W Grannis
Our objective was to analyse the cost effectiveness of computed tomography (CT) screening for lung cancer in terms of the cost per long-term survivor, which has not been evaluated to date. Estimations were computed based on data from the Surveillance, Epidemiology, and End Results registries covering years 1999–2003. The design framework of our model allowed for the incorporation of multiple values taken from the epidemiological and clinical literature to be utilised for cost inputs, scope of patients screened, diagnostic staging, and survival percentages applied separately to two cohorts: age 40–79 and 60–79 years. This enabled the analysis of over 1400 scenarios, each containing a unique set of input values, for which the estimated cost per 5-year survivor (CP5YS) was compared between the symptom-detected and proactive screening approaches. Estimated CP5YS were higher for the symptom-detected approach in all 729 scenarios analysed for the cohort ages 60–79 years, ranging from approximately $5800 to $116 700 increased cost per 5-year survivor (CP5YS). For the cohort ages 40–79 years, 75% of the 729 scenarios analysed showed increased CP5YS for the symptom-detected approach ranging from $5700 to $110 000 increased CP5YS. Total costs and total 5-year survivors were higher for the proactive screening method for all scenarios analysed across both cohorts with increases ranging from 50–256% and 98–309%, respectively. The predicted increase in long-term survival with CT screening and the potential for better utilisation of health-care dollars in terms of CP5YS, particularly when screening patients over the age of 60 years, are critically important considerations in directing effective future lung cancer management strategy.

1 November 2010 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
DEDavid S. Ettinger
David S. Ettinger
WAWallace Akerley
Wallace Akerley
GBGerold Bepler
Gerold Bepler
MBMatthew G. Blum
Matthew G. Blum
ACAndrew Chang
Andrew Chang
SYStephen C. Yang
Stephen C. Yang